Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Pediatric to Adult Transition in Sickle Cell Disease: Survey Results From Young Adult Patients
source: Acta Haematologica
year: 2019
authors: Travis K, Wood A, Yeh P, Allahabadi S, Chien LC, Curtis S, Hammond A, Kohn J, Ogugbuaja C, Rees M, Shumway J, Sheehan V
summary/abstract:Background/Aims:
We surveyed sickle cell disease (SCD) patients who transitioned from pediatric care at Texas Children’s Hematology Center (TCHC) to adult care to determine the characteristics of patients with an adult SCD provider, continuation rates of pre-transition therapies, and patient perceptions of the transition process.
Methods:
A cross-sectional study was conducted by telephone survey of 44 young adults with SCD, aged 19-29 years, who transitioned from TCHC to adult care within the last 15 years.
Results:
Findings of the 23-item questionnaire revealed that transitioned patients with current adult providers (68.2%) were more likely to have seen a provider within 6 months of transition (p = 0.023) and to have been on hydroxyurea and/or monthly blood transfusions pre-transition (p = 0.021) than transitioned patients without a provider; 83% of patients on pre-transition hydroxyurea reported continuing hydroxyurea after transition. Transition challenges included inadequate preparation, difficulty finding knowledgeable adult providers, and lack of healthcare insurance/coverage.
Conclusion:
Transition to adult providers is predicted by establishing care with an adult SCD provider within 6 months of transition and being on pre-transition disease-modifying therapy. Transition may be improved if pediatric hematology centers assist and verify adult provider contact within 6 months of transition and engage patients of all disease severity during transition.
DOI: 10.1159/000500258
read more
+myBinderRelated Content
-
Shalini Shenoy, MDDr. Shenoy is currently working as profe...
-
Sickle Cell Disease in the Adolescent FemaleSickle cell disease (SCD) is an inherite...
-
Vivien Sheehan, MD, PhDDr. Vivien Sheehan is a pediatric and ad...
-
The Teen Symposium: Engaging Adolescents and Young Adults With Sickle Cell Disease in Clinical Care and ResearchObjective: In the United States, sickle...
-
Dana-Farber/Boston Children’s Cancer and Blood Disorders CenterSpecialists in the Sickle Cell Disease P...
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
-
St. Louis Children’s HospitalThe St. Louis Children's Hospital Sickle...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.